Ropeg superior to phlebotomy alone in maintaining hematocrit control in polycythemia vera

Italy: Exposure to low-dose ropeginterferon alfa-2b (ropeg) is more effective than the standard treatment of phlebotomy and aspirin in patients with low-risk polycythemia vera (PV), a 24-month trial...

Related Keywords

Italy ,Tiziano Barbui , ,Standard Therapy ,Low Risk Patients ,Nejm Evidence ,Ropeginterferon ,Phlebotomy ,Polycythemia Vera ,Aspirin ,Hematocrit ,